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Sequencing studies have shown that optimal vaginal microbiota (VMB) are
lactobacilli-dominated and that anaerobes associated with bacterial vaginosis
(BV-anaerobes) are commonly present. However, they overlooked a less prevalent
but more pathogenic group of vaginal bacteria: the pathobionts that cause maternal
and neonatal infections and pelvic inflammatory disease. We conducted an individual
participant data meta-analysis of three VMB sequencing studies that included diverse
groups of women in Rwanda, South Africa, and the Netherlands (2,044 samples from
1,163 women in total). We identified 40 pathobiont taxa but only six were non-minority
taxa (at least 1% relative abundance in at least one sample) in all studies: Streptococcus
(54% of pathobionts reads), Staphylococcus, Enterococcus, Escherichia/Shigella,
Haemophilus, and Campylobacter. When all pathobionts were combined into one
bacterial group, the VMB of 17% of women contained a relative abundance of at
least 1%. We found a significant negative correlation between relative abundances
(ρ = −0.9234), but not estimated concentrations (r = 0.0031), of lactobacilli and
BV-anaerobes; and a significant positive correlation between estimated concentrations
of pathobionts and BV-anaerobes (r = 0.1938) but not between pathobionts and
lactobacilli (r = 0.0436; although lactobacilli declined non-significantly with increasing
pathobionts proportions). VMB sequencing data were also classified into mutually
exclusive VMB types. The overall mean bacterial load of the≥20% pathobionts VMB type
(5.85 log10 cells/µl) was similar to those of the three lactobacilli-dominated VMB types
(means 5.13–5.83 log10 cells/µl) but lower than those of the four anaerobic dysbiosis
VMB types (means 6.11–6.87 log10 cells/µl). These results suggest that pathobionts
co-occur with both lactobacilli and BV-anaerobes and do not expand as much as
BV-anaerobes do in a dysbiotic situation. Pathobionts detection/levels were increased
in samples with a Nugent score of 4–6 in both studies that conducted Nugent-scoring.
Having pathobionts was positively associated with young age, non-Dutch origin,
hormonal contraceptive use, smoking, antibiotic use in the 14 days prior to sampling,
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HIV status, and the presence of sexually transmitted pathogens, in at least one but
not all studies; inconsistently associated with sexual risk-taking and unusual vaginal
discharge reporting; and not associated with vaginal yeasts detection by microscopy.
We recommend that future VMB studies quantify common vaginal pathobiont genera.
Keywords: vaginal microbiota, bacterial vaginosis, Streptococcus, Staphylococcus, Enterococcus, Escherichia,
pathobionts, ethnicity
INTRODUCTION
Understanding of the vaginal microbiota (VMB) has increased
significantly since the turn of the century due to the increased
availability of molecular laboratory techniques such as next-
generation sequencing (van de Wijgert et al., 2014). Molecular
studies have shown that most women have a VMB consisting of
lactobacilli (most commonly Lactobacillus crispatus or L. iners),
but that vaginal dysbiosis is highly prevalent worldwide (van de
Wijgert and Jespers, 2017). The most common type of vaginal
dysbiosis is anaerobic dysbiosis, which is characterized by a
decrease of lactobacilli and an increase of fastidious anaerobes
(van de Wijgert et al., 2014). Clinicians refer to symptomatic
anaerobic dysbiosis as bacterial vaginosis (BV): patients typically
have mild vaginal inflammation and a fishy-smelling vaginal
discharge. It should be noted, however, that anaerobic dysbiosis
is also frequently asymptomatic. The VMB of most women
with anaerobic dysbiosis consists of a highly diverse mixture
of fastidious anaerobes, usually including Gardnerella vaginalis.
However, a substantial proportion of women with anaerobic
dysbiosis are dominated by G. vaginalis, and this type of low
diverse anaerobic dysbiosis is often overlooked. Recent studies
have suggested that these women might be more difficult to treat,
potentially due to the presence of a G. vaginalis-initiated vaginal
mucosal biofilm (Verwijs et al., 2019a).
Another clinically relevant type of vaginal dysbiosis that
has systematically been overlooked is the presence of bacterial
pathobionts in the VMB (van de Wijgert and Jespers, 2017).
Microbiologists define the term pathobiont as any potentially
pathological organism which, under normal circumstances,
lives as a non-harming symbiont. In the vaginal niche, this
would include—among others—Streptococcus agalactiae (Group
B streptococcus), Staphylococcus aureus, and species in the
Enterobacteriaceae family. These bacteria have often been
associated with maternal and neonatal infections (Cools et al.,
2016; Black et al., 2018), as well as invasive infections in non-
pregnant women such as pelvic inflammatory disease (Brunham
et al., 2015). Some clinical researchers have hypothesized
that a distinct type of vaginitis (desquamative inflammatory
vaginitis), which is characterized by much more severe vaginal
inflammation than BV and with desquamation of vaginal
epithelial cells including parabasal cells (Sobel, 1994; Paavonen
and Brunham, 2018), may be caused by pathobionts in the
VMB (Donders et al., 2017). Two cases that appear to have
been triggered by toxic shock syndrome toxin-1-producing
Staphylococcus aureus strains have indeed been reported (Pereira
et al., 2013). However, others believe that the condition is caused
by estrogen deficiency or an immunologic disorder, and that
vaginal dysbiosis develops secondarily (Sobel et al., 2011). A
recent study found that most patients with vaginitis, parabasal
cells, and lactobacilli-deficiency by microscopy did not have
consistent VMB patterns by VMB sequencing (Oerlemans, 2019).
We conclude that there is sufficient evidence to consider VMB
pathobionts clinically relevant, but that the evidence-base related
to both symptoms and complications is weak.
An important reason why the evidence-base is weak is
because pathobionts are often not assessed properly. For
example, neonatal invasive infection studies have focused on
only one pathobiont (S. agalactiae) by culture (Kwatra et al.,
2016), and VMB sequencing studies have systematically under-
reported pathobionts. Authors of such studies typically use
bioinformatical methods, such as hierarchical clustering, to
summarize the sequencing data into a few VMB types. The first
set of VMB types were published by Ravel et al. (2011) based
on a study in asymptomatic American women: they referred
to these as community state types I (L. crispatus-dominated),
II (L. gasseri-dominated), III (L. iners-dominated), IV (diverse
group), and V (L. jensenii-dominated (Ravel et al., 2011). The
only pathobiont that was mentioned in this publication was
Streptococcus, as one of the taxa included in the “diverse group.”
However, hierarchical clustering only takes relative abundances
into account and not the pathogenic potential of individual
bacteria. Pathobionts usually occur at lower levels than BV-
anaerobes, but have a higher pathogenic potential: these lower
levels may therefore be clinically relevant. Because pathobionts
rarely dominate the VMB, samples that contain pathobionts are
often classified based on the other bacteria that are also present in
that sample. For example, a sample containing 70% L. iners and
30% S. agalactiae would be classified as community state type III
(L. iners-dominated) in most studies.
We believe that this vaginal pathobionts knowledge gap is
hampering clinical progress in the field. We therefore performed
an individual participant data meta-analysis of three VMB
sequencing studies that enrolled diverse groups of women in
Rwanda, South Africa, and the Netherlands (2,044 samples from
1,163 women in total), with as main aim to describe the presence
and levels of all pathobionts identified in the sequencing data,
their correlations with lactobacilli and BV-anaerobes, and their
associations with participant sociodemographic, behavioral, and
clinical/laboratory characteristics.
MATERIALS AND METHODS
Studies Included in the Meta-Analysis
We performed an individual participant data meta-analysis of
three VMB sequencing studies that were conducted in three
different countries to account for regional and ethnic differences
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in VMB composition: (1) a clinical trial of intermittent oral
metronidazole or vaginal probiotic use in Kigali, Rwanda
(referred to as the Rwanda VMB study); (2) the VMB sub-
study of the South African HPV in Africa Research Partnership
(HARP) study in Johannesburg, South Africa; and (3) the VMB
sub-study of the Healthy Life in an Urban Setting (HELIUS)
study in Amsterdam, the Netherlands.
The Rwanda VMB study screened HIV-negative, non-
pregnant, pre-menopausal women at high risk of sexually
transmitted infections (STIs) for BV (van de Wijgert et al.,
2020a). Women with BV were treated with metronidazole
for seven days, and when cured of BV and other urogenital
infections, were randomized to no intervention, or intermittent
use of oral metronidazole or two different lactobacilli-containing
vaginal probiotics for 2 months. The lactobacilli contained in
the vaginal probiotics did not include any naturally occurring
vaginal lactobacilli. Women were sampled at screening (start
of BV/urogenital infection treatment, if applicable), enrollment
(start of the interventions), Day 7, Month 1, Month 2 (cessation
of the interventions), and Month 6. The study found that all
three interventions were safe and affected naturally occurring
lactobacilli and BV-anaerobes (in favor of the lactobacilli,
particularly L. iners), but not pathobionts. However, to avoid any
bias in this meta-analysis due to exposure to interventions, we
conducted analyses that included lactobacilli and BV-anaerobes
levels on VMB data that were not influenced by the interventions
(N = 366 of 629 samples): data from samples collected in
all randomization groups at the screening visit prior to any
treatments (if applicable) and at theMonth 6 visit (4 months after
cessation of the interventions), as well as samples collected in the
no intervention group at the Month 1 and Month 2 visits.
The VMB sub-study of the HARP study was a nested case-
control study within a prospective cohort study conducted in
Johannesburg, South Africa (van de Wijgert et al., 2020b).
The study enrolled HIV-positive women and investigated
the associations of VMB composition with high-risk human
papillomavirus (hrHPV) and cervical intraepithelial neoplasia
(CIN) acquisition, clearance, and/or persistence. All but one
participant were of sub-Saharan African origin. Samples for
VMB analyses were collected at baseline (N = 445) and at
endline (N = 414), a median of 16 months later. The study
concluded that hrHPV infection (and/or increased sexual risk-
taking) likely causes anaerobic vaginal dysbiosis, but that a
bidirectional relationship is also possible. Furthermore, in this
population, dysbiosis did not increase CIN2+ risk, but CIN2+
increased dysbiosis risk. Since the study did not include an
intervention, we used all available VMB data for the analyses
presented in this paper.
The HELIUS study is a large, multi-ethnic cohort study in
Amsterdam, the Netherlands (Snijder et al., 2017). Sampling
was stratified by ethnic group and included the six largest
ethnic groups in the city (Dutch, African Surinamese, South-
Asian Surinamese, Turkish, Moroccan, and Ghanaian). In a sub-
sample, a cross-sectional study on the association of ethnicity
with VMB composition was performed (Borgdorff et al., 2017).
For this sub-study, vaginal samples of 546 pre-menopausal
women were sequenced. The most prevalent VMB composition
in ethnically Dutch women was a L. crispatus-dominated VMB,
in African Surinamese and Ghanaian women a polybacterial
G. vaginalis-containing VMB, and in the other ethnic groups
a L. iners-dominated VMB. This study did not include an
intervention either, and we therefore used all available VMB data
for the analyses presented in the current paper.
Sequencing and Other Laboratory Methods
All three studies extracted DNA from vaginal swabs and
conducted 16S rRNA gene sequencing of the V3–V4 variable
regions on Illumina platforms (SanDiego, CA, USA) as described
by Fadrosh et al. (2014). Standard diagnostic tests were used
to test for STIs (all three studies), and BV and vulvovaginal
candidiasis (Rwanda VMB and HARP studies only). There
were some differences in sequencing and diagnostic methods
used, as outlined in Table 1. Because of these differences, we
conducted all analyses on each study separately as well as the
three studies combined.
The BactQuant 16S rRNA gene qPCR (Liu et al., 2012) was
only done in the Rwanda VMB study (N = 379, of which 158
samples were not influenced by the interventions). The 16S
rRNA gene concentration per sample was used to convert the
relative abundances of that sample into estimated concentrations
as previously described (van de Wijgert et al., 2020a). We used
both relative abundances as well as estimated concentrations for
the Rwanda VMB study, but only had relative abundances for the
other two studies.
Sequencing Data Processing
The 16S rRNA gene sequencing and initial data processing
yielded two-dimensional tables with samples and bacterial
taxa on the axes, and relative abundances in the cells, for
each of the three studies. DADA2 assigns amplicon sequence
variants (ASVs) to taxa (in the Rwanda VMB study) and
Swarm and USEARCH assign them to operational taxonomic
units (OTUs; in the HARP and HELIUS studies, respectively).
Details on quality control and cleaning of reads, taxonomic
assignments, conversion of read counts into relative abundances,
and rarefaction are summarized in Table 1 and explained in the
original publications. The three study-specific relative abundance
tables were combined into a single table, and all subsequent data
processing steps were redone for the combined table (i.e., are
slightly different from the original publications) to ensure that
they were identical for the three studies.
Data reduction for biostatistical modeling was done in three
different ways. First, the Simpson diversity index (1-D) was
calculated for each sample, ranging from 0 (no diversity) to
1 (infinite diversity). Second, each ASV/OTU was assigned to
one of four “bacterial groups” based on the published literature
(Supplementary Material 1) as follows: (1) lactobacilli; (2) BV-
anaerobes; (3) pathobionts; and (4) a rest group called “other
bacteria” (which contained mostly skin and Bifidobacteria).
Pathobionts were defined as all bacterial taxa that have been
reported in the literature as having been associated with invasive
disease, and are not typically associated with BV; we also
included STI pathogens in this category because their mean
relative abundances were too low to justify a separate bacterial
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TABLE 1 | Main study characteristics of the three studies.
VMB Rwandaa HARP South Africaa HELIUS Netherlandsa
Number of women 162 (68 randomized) 455 546
Number of baseline samples 162 445 546
Total number of samples 629 (366 not influenced by
interventions)
869 546
Years samples collected 2015–2016 2011–2014 2011–2013
Year samples sequenced 2017 2016 2014
Study location Kigali Johannesburg Amsterdam
Study population HIV-negative women with high sexual
risk
HIV-positive women on cART (2/3) or
not on cART (1/3)
Random samples of city population,
stratified by ethnic group
Sequencing methods
Sequencing laboratory University of Liverpool, Center for
Genomic Research
University of Liverpool, Center for
Genomic Research
Amsterdam University Medical
Center, location VUmc
Type of vaginal samples Vaginal swab frozen dry the same day
at −80◦C and shipped to Liverpool
on dry ice.
Vaginal swab in Boonfix, stored and
shipped to Liverpool at room
temperature.
Vaginal swab frozen dry at −20◦C
after at most 6 days at 2–8◦C.
DNA extraction method Lysozyme lysis with bead-beating,
followed by Qiagen DNeasy Blood
and Tissue kit
Lysozyme lysis (no bead-beating)
followed by Qiagen DNeasy Blood
and Tissue kit
Lysozyme, mutanolysin, lysostaphin
lysis with bead-beating followed by
proteinase K/RNase A and
ChemaGen extraction robot
16S sequencing platform Illumina HiSeq (rapid mode; 2 ×
300bp)
Illumina HiSeq (rapid mode; 2 ×
300bp)
Illumina MiSeq (2 × 300bp)
16S variable region V3–V4 V3–V4 V3–V4
Taxonomic assignment and unit
of analysis
DADA2 v1.4.0
ASV
Swarm v2.1.13
OTU
USEARCH v5.2.236
OTU
Reference databases Silva v128, NCBI, Vaginal 16S rDNA
Reference Database by Srinivasan
et al.
Silva v128, NCBI GreenGenes v13.8, NCBI, Vaginal
16S rDNA Reference Database by
Srinivasan et al.
Rarefaction At 1,111 reads At 1,039 reads None, but all samples with <100
reads discarded
Mean read count per sample 374,543 122,490 25,392
Unique ASVs/OTUsb 401 (177 non-minority) 1,981 (246 non-minority) 455 (141 non-minority)
BactQuant assay donec Yes No No
Diagnostic tests
Bacterial vaginosis Nugent, Amsel Nugent Not done
Yeasts Wet mount microscopy Gram stain microscopy Not done
Trichomonas vaginalis Wet mount microscopy and InPouch
culture
APTIMA Combo 2 PCR APTIMA PCR
Chlamydia trachomatis and
Neisseria gonorrhoeae
Presto or GeneXpert real-time PCR APTIMA Combo 2 PCR APTIMA Combo 2 PCR
Syphilis Spinreact RPR + TPHA Immutrep RPR + TPHA Not done
HIV-1 National algorithm (serology) National algorithm (serology) Not done
Herpes simplex type 2 Kalon IgG2 ELISA Kalon IgG2 ELISA Not done
HPV Not done Digene HC-II, CareHPV, INNO-LiPA
HPV Genotyping Extra
SPF10-PCR-DEIA/LiPA25 system
version 1
ASV, Amplicon Sequence Variant; cART, combination antiretroviral therapy for HIV; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; HPV, human
papillomavirus; IgG, Immunoglobulin G; NCBI, National Center for Biotechnology Information; OTU, Operational Taxonomic Unit; PCR, polymerase chain reaction; RPR, Rapid Plasma
Reagin test; TPHA, Treponema pallidum Hemagglutination Assay.
aDetails of procedures and supplies/databases used can be found in the original publications (Borgdorff et al., 2017; van de Wijgert et al., 2020a,b).
bNon-minority is defined as at least 1% in at least one sample. The number of minority OTUs was higher in the HARP study than in the other two studies because OTUs matching to the
same or overlapping taxa were not merged. This has, however, not affected the analyses in this paper, which were based on bacterial groups and a select number of non-minority taxa.
cBactQuant is a commercial assay that quantifies 16S genes in a sample by quantitative PCR (Liu et al., 2012).
group. For each sample, relative abundances of ASVs/OTUs
belonging to the same bacterial group were summed. This
resulted in four relative abundances (one for each bacterial
group) per sample, which sum to one in total. For example,
one sample could contain 0.5 (50%) lactobacilli reads, 0.4 (40%)
BV-anaerobes reads, 0.08 (8%) pathobionts reads, and 0.02 (2%)
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other bacteria reads. Third, we classified samples into nine
VMB types (with each sample assigned to only one VMB type):
(1) Lactobacillus iners-dominated (Li; ≥75% relative abundance
of lactobacilli of which L. iners was the most common); (2)
L. crispatus-dominated (Lcr; also ≥75% lactobacilli of which
L. crispatus was the most common); (3) dominated by other
Lactobacillus species (Lo; also containing ≥75% lactobacilli);
(4) lactobacilli and anaerobes (LA; ≥25% lactobacilli with the
remainder BV-anaerobes); (5) high diversity BV-anaerobes with
≥10% G. vaginalis presence (BV_GV); (6) high diversity BV-
anaerobes with <10% G. vaginalis presence (BV_noGV); (7) G.
vaginalis-dominated (GV; G. vaginalis ≥50%); (8) substantial
presence of pathobionts (PB; ≥20% pathobiont taxa); and (9)
Bifidobacterium-dominated (BD; ≥50% Bifidobacteria).
Statistical Analyses and Figures
Statistical analyses were performed using Stata version 13
(StataCorp, College Station, TX, USA) and R version 3.2.3 (R
foundation for Statistical Computing 2016, Vienna, Austria).
All analyses were cross-sectional, sometimes including samples
collected at baseline only (one sample per woman) and
sometimes including all samples (in case of the Rwanda VMB
and HARP studies, more than one sample per woman). Women
in the Rwanda VMB study were exposed to antibiotic and/or
probiotic interventions, and samples that could potentially have
been influenced by these interventions were excluded from
most analyses as described above and as indicated in the tables
and text. Unadjusted differences between groups of interest
were tested by Fisher’s exact test for binary variables, Chi-
squared test for categorical variables, and Kruskal-Wallis test for
continuous variables. Pathobiont levels (relative abundances or
estimated concentrations) were correlated with those of other
bacterial groups or taxa by Spearman’s rank correlation when all
samples were included and by Pearson’s correlation coefficient
when samples with <1% pathobionts were excluded. To assess
sociodemographic, behavioral, and clinical determinants of
pathobionts detection (≥1% compared to <1%) and levels, we
used unadjusted logistic regression models for analyses including
one sample per woman, and Kruskal-Wallis tests for analyses of
pathobionts levels that included all samples. The heatmap was
made with the gplots package in R (Warnes et al., 2016), bar charts
in Stata, and correlation matrices with the corrplot package in R
(Taiyun, 2019).
RESULTS
Participant Characteristics
Themedian age in the three studies combinedwas 30 years (inter-
quartile range 26–34) and most women were non-pregnant by
design (Table 2). The majority of women in the Rwanda VMB
study were at high risk of HIV/STI by design: 93.2% reported
two or more partners in the month prior to the baseline visit
and 76.6% reported no or inconsistent condom use. Much
lower proportions of women in the HARP study reported these
current sexual risk behaviors but they were all HIV-positive
by design. Women in the HELIUS study were not selected
based on sexual risk or HIV-status. The proportions of women
reporting sexual risk behaviors could be considered average for a
young, urban, Dutch population, but with differences by ethnic
group: proportions were highest in women of Dutch origin,
followed by Dutch women of sub-Saharan African (African
Surinamese or Ghanaian) origin, and Dutch women of Turkish,
Moroccan, or South Asian Surinamese origin. Current hormonal
contraceptive use varied substantially between studies and ethnic
groups, as did current smoking habits. Almost half of the women
(39.4–45.1%; not assessed in the HARP study) reported current
urogenital symptoms, but none of them had sought care for
them. Laboratory-confirmed viral and bacterial STI prevalences
were high in the Rwanda VMB study and low in the HELIUS
study, whereas viral STI prevalences were high and bacterial STI
prevalences low in the HARP study (consistent with high past but
low current sexual risk). Antibiotic use in the 2 weeks prior to
baseline was rare.
Overall Vaginal Microbiota Characteristics
A heatmap of key taxa for all 2,044 samples from all three studies
combined is shown in Supplementary Material 2, Table S1.
In Table 3, Figure 1, VMB study samples were stratified by
exposure to interventions, and HELIUS study samples by ethnic
group. Mean Simpson diversity indexes and mean relative
abundances of bacterial groups, and key taxa within these
groups, differed significantly between the three studies and
these pre-specified strata within studies (Table 3, Figure 1A).
By far the most common bacterial groups in all studies
and strata were the lactobacilli and BV-anaerobes, with mean
relative abundances ranging from 0.46 to 0.73 and 0.25 to
0.49, respectively. The differences between studies and strata
were as expected, with lower lactobacilli and higher BV-
anaerobes proportions in women with higher sexual risk profiles
and/or STI exposures and in women of sub-Saharan African
ethnicities. In contrast, Rwanda VMB study participants who
had recently been exposed to antibiotic/probiotic interventions
had higher lactobacilli and lower BV-anaerobes proportions.
The differences in L. crispatus mean relative abundance were
especially striking, ranging from only 0.03 in the Rwanda VMB
study samples that were not influenced by interventions to 0.38
in the HELIUS samples from women of Dutch origin. Mean
relative abundances for pathobionts and the “other bacteria”
group were low in all studies and strata, ranging from 0.01
to 0.07 and 0 to 0.05, respectively. The mean pathobionts
relative abundance did not show a clear pattern between studies
and strata but was lowest in the HELIUS women of Dutch
origin. Estimated concentrations were only available for the
Rwanda VMB study, and mean estimated concentrations in
log10 cells/µl were 5.12 for lactobacilli (mostly consisting of L.
iners), 5.17 for BV-anaerobes, 2.18 for pathobionts, and 1.92
for other bacteria in samples not influenced by interventions
(Table 3). The mean pathobionts estimated concentration was
therefore 871 times lower than the mean lactobacilli estimated
concentration, and 977 times lower than the mean BV-anaerobes
estimated concentration.
The VMB types for all samples combined (N = 2,044)
were distributed as follows: Li 31.6%, Lcr 10.5%, Lo 2.4%, LA
15.8%, BV_GV 20.3%, BV_noGV 5.5%, GV 8.3%, PB 5.2%,
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TABLE 2 | Baseline characteristics by study, and by ethnic group within the HELIUS study.
VMB
Rwanda
(N = 162)
HARP
South Africa
(N = 455)
HELIUS
Netherlands
Sub-Saharan
African origina
(N = 183)
HELIUS
Netherlands
Turkish,
Moroccan,
South-Asian
originb (N = 264)
HELIUS
Netherlands
Dutch origin
(N = 99)
All studies
(N = 1,163)
P-
valuec
Age (median, IQR) 30 (27–34) 34 (30–39) 26 (22–30) 27 (23–31) 26 (22-30) 30 (26–34) <0.001
Currently pregnant (n%)d 6 (3.7) 0 0 0 0 6 (0.5) <0.001
Contraceptive use if not pregnant (n%)
- None or condom use only
- Oral contraceptione
- Progestin-only injectable
- Progestin-only implant
- Any intrauterine devicef
- Contraceptive ring
N = 156
64 (41.0)
16 (10.3)
45 (28.9)
28 (18.0)
3 (1.9)
0
340 (74.7)
23 (5.1)
86 (18.9)
6 (1.3)
0
0
97 (53.6)
61 (33.7)
1 (0.6)
1 (0.6)
20 (11.1)
1 (0.6)
148 (56.3)
88 (33.5)
0
5 (1.9)
20 (7.6)
2 (0.8)
27 (27.7)
46 (46.5)
1 (1.0)
0
20 (20.2)
5 (5.1)
N = 1,154
676 (58.6)
234 (20.3)
133 (11.5)
40 (3.5)
63 (5.5)
8 (0.7)
<0.001
Currently using hormonal contraception or
is pregnant (n%)g 95 (58.6) 115 (25.3)
N = 161
64 (39.8)
N = 243
95 (39.1)
N = 79
52 (65.8)
N = 1,100
421 (38.3) <0.001
Current smoker (n%)
NAh 25 (5.5) 27 (14.8) 68 (25.9) 30 (30.3)
N = 999
150 (15.0) <0.001
Used any antibiotic in past 14 days (n%)
0 NA 8 (4.4) 7 (2.7) 4 (4.0)
N = 706
19 (2.7) 0.024
Reported any type of vaginal cleansing
(n%)i
N = 64
11 (17.2) 179 (39.3) 47 (25.8) 72 (27.7) 18 (18.2)
N = 1,064
327 (30.7) <0.001
Number of sex partners in period prior to samplingj
- None
- One
- Two or more
0
11 (6.8)
151 (93.2)
77 (17.0)
352 (77.5)
25 (5.5)
54 (29.7)
100 (55.0)
28 (15.4)
103 (39.0)
142 (53.8)
19 (7.2)
23 (23.2)
51 (51.5)
25 (25.3)
257 (22.1)
656 (56.4)
248 (21.3)
<0.001
Frequency of condom use (n%)k
- Never
- Inconsistent
- Consistent
- NA (no sexual partner)
9 (5.6)
115 (71.0)
38 (23.5)
0
24 (5.3)
129 (28.4)
221 (48.6)
81 (17.8)
60 (32.0)
42 (23.1)
26 (14.3)
54 (29.7)
99 (37.6)
39 (14.8)
22 (8.4)
103 (39.2)
43 (43.4)
26 (26.3)
7 (7.1)
23 (23.2)
235 (20.2)
351 (30.2)
314 (27.1)
262 (22.5)
<0.001
Reported any urogenital symptoms (n%)
73 (45.1) NA 73 (39.9) 117 (44.3) 39 (39.4)
N = 708
302 (42.7) 0.644
Reported unusual vaginal discharge (n%)
21 (13.0) NA 25 (13.7) 57 (21.6) 16 (16.2)
N = 708
119 (16.8) 0.069
Positive HIV test (n%) 16 (9.9) 455 (100) 0 0 0 471 (40.5) <0.001
Yeasts by microscopy (n%) N = 140
14 (10.0)
N = 445
34 (7.6) NA NA NA
N = 585
48 (8.2) 0.380
Trichomonas vaginalis by culture/NAAT
(n%)
N = 138
17 (12.3) 71 (15.6) 6 (3.3) 1 (0.4) 0
N = 1,139
95 (8.3) <0.001
Chlamydia trachomatis by NAAT (n%) N = 139
30 (21.6) 24 (5.3) 10 (5.5) 6 (2.3) 2 (2.0)
N = 1,140
72 (6.3) <0.001
(Continued)
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TABLE 2 | Continued
VMB
Rwanda
(N = 162)
HARP
South Africa
(N = 455)
HELIUS
Netherlands
Sub-Saharan
African origina
(N = 183)
HELIUS
Netherlands
Turkish,
Moroccan,
South-Asian
originb (N = 264)
HELIUS
Netherlands
Dutch origin
(N = 99)
All studies
(N = 1,163)
P-
valuec
Neisseria gonorrhoeae by NAAT (n%) N = 139
18 (13.0) 10 (2.2) 0 0 0
N = 1,140
28 (2.5) <0.001
Mycoplasma genitalium by NAAT (n%) NA 38 (8.4) NA NA NA NA NA
Active syphilis by serology (n%)
13 (8.0)
N = 452
3 (0.7) NA NA NA
N = 614
16 (2.6) <0.001
Herpes simplex virus type 2 by serology
(n%) 109 (67.3)
N = 453
432 (95.4) NA NA NA
N = 615
541 (88.0) <0.001
Any high-risk HPV by PCR (n%)
NA 363 (79.8) 56 (30.6) 66 (25.0) 41 (41.4)
N = 1,001
526 (52.6) <0.001
HPV, human papilloma virus; IQR, inter-quartile range; NA, not applicable; NAAT, nucleic acid amplification test; PCR polymerase chain reaction.
The unit of analysis is one sample (collected at baseline) per woman.
a Included Dutch women of African Surinamese and Ghanaian origin.
b Included Dutch women of South-Asian Surinamese, Moroccan, and Turkish origin.
cUsing the Fisher’s exact test for binary variables, the Chi-squared test for categorical variables, and Kruskal-Wallis test for continuous variables.
dPregnant women were not eligible for enrollment in any of the studies, but six women screened for the Rwanda VMB study were pregnant when the baseline vaginal swabs were taken, prior to enrollment.
e Includes combined and progestin-only oral contraception.
f In the VMB and HARP studies, only copper intrauterine devices were used. In the HELIUS study, women may have used either a copper or hormone-containing intrauterine device. One HELIUS participant used both an intrauterine
device and a pill and she is included here.
gExcluding HELIUS participants who used intrauterine devices (including the participant who used an intrauterine device and a pill).
hThis question was not asked in the Rwanda VMB study but we know from previous studies in the same population that women rarely smoke.
i In the Rwanda VMB study, only participants who were subsequently randomized to the interventions were asked this question.
jThe recall period was 1 month in the Rwanda VMB study, 3 months in the HARP study, and 6 months in the HELIUS study. In the Rwanda VMB study, the frequencies were as follows for 12 months recall: no partners 0%, one partner
2.5%, and two or more partners 97.5%.
k The recall period was 2 weeks in the Rwanda VMB study, 3 months in the HARP study, and 6 months in the HELIUS study.
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TABLE 3 | Overview of VMB composition characteristics by study, stratified by intervention exposure (VMB Rwanda) and ethnic group (HELIUS).
VMB Rwanda
(not influenced by
interventions)a
VMB Rwanda
(influenced by
interventions)a
HARP
South Africa
HELIUS
Sub-Saharan
African originb
HELIUS
Turkish,
Moroccan,
South-Asian
originc
HELIUS
Dutch origin
All groups P-valued
Samples with relative abundance data available
(N)
Samples with estimated concentration data
available (N)
366
158
263
221
869
0
183
0
264
0
99
0
2,044
379
NA
Nugent score category (n %)e:
- 0–3
- 4–6
- 7–10
N = 231
79 (34.2)
27 (11.7)
125 (54.1)
N = 227
111 (48.9)
40 (17.6)
76 (33.5)
N = 445
151 (33.9)
102 (22.9)
192 (43.2)
NA NA NA N = 903
341 (37.8)
169 (18.7)
393 (43.5)
<0.001
Simpson diversity index (1-D; mean, 95% CI)f 0.53 (0.50–0.56) 0.40 (0.36–0.44) 0.54 (0.52–0.56) 0.39 (0.35–0.43) 0.34 (0.31–0.38) 0.32 (0.27–0.37) 0.47 (0.46–0.48) <0.001
VMB types (n %)g:
- L. iners-dominated (Li)
- L. crispatus-dominated (Lcr)
- Dominated by other lactobacilli (Lo)
- Lactobacilli plus anaerobes (LA)
- Polybacterial G. vaginalis-containing (BV_GV)
- Polybacterial with little G. vaginalis (BV_noGV)
- G. vaginalis-dominated (GV)
- Pathobionts-containing (PB)
119 (32.5)
10 (2.7)
18 (4.9)
45 (12.3)
102 (27.9)
21 (5.7)
26 (7.1)
25 (6.8)
128 (48.7)
7 (2.7)
10 (3.8)
41 (15.6)
36 (13.7)
2 (0.8)
15 (5.7)
24 (9.1)
237 (27.3)
65 (7.5)
5 (0.6)
188 (21.6)
215 (24.7)
75 (8.6)
49 (5.6)
33 (3.8)
49 (26.8)
33 (18.0)
5 (2.7)
12 (6.6)
38 (20.8)
4 (2.2)
35 (19.1)
7 (3.8)
89 (34.6)
61 (23.7)
5 (2.0)
28 (10.9)
15 (5.8)
10 (3.9)
32 (12.5)
17 (6.6)
24 (24.5)
38 (38.8)
6 (6.1)
8 (8.2)
8 (8.2)
0
13 (13.3)
1 (1.0)
646 (31.6)
214 (10.5)
49 (2.4)
322 (15.8)
414 (20.3)
112 (5.5)
170 (8.3)
107 (5.2)
<0.001
Relative abundance of VMB bacterial groups (mean, 95% CI):
- Total lactobacilli
- L. iners
- L. crispatus
- Other lactobacilli
- Total BV-anaerobes
- G. vaginalis
- A. vaginae
- Prevotella species
- Other BV-anaerobes
- Total pathobionts
- Streptococcus species
- Staphylococcus species
- Escherichia/Shigella species
- Other pathobiontsh,i
- Total other bacteria
0.46 (0.42–0.51)
0.36 (0.32–0.40)
0.03 (0.02–0.05)
0.07 (0.05–0.09)
0.48 (0.44–0.52)
0.18 (0.16-0.20)
0.03 (0.02-0.04)
0.07 (0.06–0.08)
0.20 (0.18–0.23)
0.05 (0.03–0.07)
0.04 (0.02–0.05)
0 (0–0.01)
0.01 (0–0.02)
0 (0–0)
0 (0–0)
0.63 (0.59–0.68)
0.53 (0.48–0.58)
0.04 (0.02–0.06)
0.07 (0.04–0.09)
0.30 (0.25–0.34)
0.15 (0.12–0.17)
0.01 (0.01–0.02)
0.03 (0.02–0.04)
0.10 (0.08–0.12)
0.07 (0.04–0.09)
0.05 (0.03–0.07)
0 (0–0)
0.01 (0–0.02)
0.01 (0–0.01)
0 (0–0.01)
0.47 (0.44–0.50)
0.37 (0.34–0.39)
0.08 (0.07–0.10)
0.02 (0.01–0.02)
0.49 (0.46–0.52)
0.17 (0.15–0.18)
0.03 (0.02–0.03)
0.06 (0.06–0.07)
0.23 (0.22–0.25)
0.03 (0.02–0.04)
0.02 (0.01–0.03)
0 (0–0)
0 (0–0)
0 (0–0)
0.01 (0.01–0.01)
0.52 (0.45–0.58)
0.30 (0.25–0.36)
0.18 (0.13–0.23)
0.04 (0.02–0.06)
0.44 (0.37–0.50)
0.23 (0.19–0.27)
0.09 (0.07–0.11)
0.02 (0.01–0.03)
0.10 (0.07–0.12)
0.03 (0.01–0.05)
0.02 (0.01–0.04)
0 (0–0)
0 (0–0.01)
0 (0–0)
0.01 (0.01–0.02)
0.64 (0.59–0.69)
0.34 (0.29–0.39)
0.24 (0.19–0.28)
0.06 (0.04–0.08)
0.27 (0.22–0.31)
0.16 (0.12–0.19)
0.04 (0.03–0.05)
0.02 (0.01–0.03)
0.05 (0.04–0.06)
0.04 (0.02–0.06)
0.03 (0.02–0.04)
0 (0–0)
0 (0–0.01)
0.01 (0–0.01)
0.05 (0.03–0.07)
0.73 (0.65–0.80)
0.28 (0.20–0.35)
0.38 (0.29–0.46)
0.08 (0.04–0.11)
0.25 (0.17–0.32)
0.16 (0.10–0.21)
0.06 (0.03–0.08)
0.01 (0–0.01)
0.03 (0.02–0.04)
0.01 (0–0.03)
0 (0–0.01)
0.01 (0–0.03)
0 (0–0)
0 (0–0)
0.01 (0.00–0.03)
0.53 (0.51–0.55)
0.37 (0.36–0.39)
0.11 (0.10–0.12)
0.04 (0.04–0.05)
0.42 (0.40–0.44)
0.17 (0.16–0.18)
0.04 (0.03–0.04)
0.05 (0.04–0.05)
0.16 (0.15–0.17)
0.04 (0.03–0.04)
0.03 (0.02–0.03)
0 (0–0)
0 (0–0.01)
0 (0–0)
0.01 (0.01–0.02)
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
(Continued)
F
ro
n
tie
rs
in
C
e
llu
la
r
a
n
d
In
fe
c
tio
n
M
ic
ro
b
io
lo
g
y
|w
w
w
.fro
n
tie
rsin
.o
rg
8
A
p
ril2
0
2
0
|V
o
lu
m
e
1
0
|
A
rtic
le
1
2
9
va
n
d
e
W
ijg
e
rt
e
t
a
l.
P
a
th
o
b
io
n
ts
in
th
e
V
a
g
in
a
lM
ic
ro
b
io
ta
TABLE 3 | Continued
VMB Rwanda
(not influenced by
interventions)a
VMB Rwanda
(influenced by
interventions)a
HARP
South Africa
HELIUS
Sub-Saharan
African originb
HELIUS
Turkish,
Moroccan,
South-Asian
originc
HELIUS
Dutch origin
All groups P-valued
Relative abundance total pathobionts categorical (n %):
<1% of reads
1%–<10%
10%–<20%
20%–<50%
50% or more
467 (74.2)
87 (13.8)
26 (4.1)
24 (3.9)
25 (4.0)
190 (72.2)
36 (13.7)
13 (4.9)
10 (3.8)
14 (5.3)
726 (83.5)
88 (10.1)
22 (2.5)
18 (2.1)
15 (1.7)
162 (88.5)
14 (7.7)
0
2 (1.1)
5 (2.7)
203 (76.9)
42 (15.9)
2 (0.8)
10 (3.8)
7 (2.7)
87 (87.9)
10 (10.1)
1 (1.0)
0
1 (1.0)
1,645 (80.5)
241 (11.8)
51 (2.5)
54 (2.6)
53 (2.6)
<0.001
Estimated concentration of VMB bacterial groups in log10 cells/µl (mean, 95% CI):
- Total lactobacilli
- L. iners
- L. crispatus
- Other lactobacilli
- Total BV-anaerobes
- G. vaginalis
- A. vaginae
- Prevotella species
- Other BV-anaerobes
- Total pathobionts
- Streptococcus species
- Staphylococcus species
- Enterococcus species
- Escherichia/Shigella species
- Campylobacter species
- Haemophilus species
- Other pathobiontsi,j
- Total other bacteria
5.12 (4.97–5.27)
4.78 (4.60–4.97)
0.64 (0.48–0.80)
2.29 (2.08–2.50)
5.17 (4.99–5.35)
4.48 (4.25–4.71)
2.80 (2.53–3.07)
3.00 (2.75–3.25)
4.30 (4.09–4.51)
2.18 (1.96–2.40)
1.59 (1.38–1.81)
0.46 (0.35–0.58)
0.17 (0.09–0.25)
0.50 (0.37–0.63)
0.12 (0.05–0.19)
0.07 (0.02–0.12)
0.36 (0.18–0.53)
1.92 (1.72–2.11)
4.84 (4.58–5.10)
4.56 (4.25–4.87)
0.44 (0.23–0.65)
1.73 (1.40–2.06)
5.74 (5.48–6.01)
5.08 (4.75–5.40)
3.97 (3.56–4.38)
4,01 (3.65–4.38)
5.08 (4.79–5.37)
2.04 (1.69–2.38)
1.47 (1.14–1.80)
0.41 (0.24–0.58)
0.06 (0–0.13)
0.35 (0.17–0.54)
0.17 (0.04–0.29)
0.08 (0–0.16)
0.40 (0.25–0.55)
1.92 (1.61–2.31)
NA NA NA NA 5.32 (5.15–5.49)
4.95 (4.72–5.17)
0.78 (0.56–1.01)
2.69 (2.43–2.96)
4.76 (4.53–4.99)
4.05 (3.75–4.35)
1.96 (1.64–2.29)
2.28 (1.97–2.59)
3.75 (3.48–4.02)
2.28 (1.99–2.57)
1.68 (1.39–1.97)
0.50 (0.34–0.66)
0.24 (0.12–0.37)
0.61 (0.42–0.79)
0.09 (0.01–0.17)
0.07 (0–0.13)
0.38 (0.27–0.49)
1.92 (1.66–2.17)
0.005
0.051
0.049
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.318
0.326
0.400
0.055
0.030
0.239
0.860
0.579
1.00
A, Atopobium; BV, bacterial vaginosis; CI, confidence interval; G, Gardnerella; L, Lactobacillus; NA, not assessed/applicable; VMB, vaginal microbiota.
The unit of analysis is one sample. Cells contain at most five missing values unless otherwise indicated.
aSamples collected at the screening and Month 6 visits in all randomization groups, and at the Month 1 and Month 2 visits in the no–intervention group, were considered not influenced by the interventions.
b Included Dutch women of African Surinamese and Ghanaian origin.
c Included Dutch women of South–Asian Surinamese, Moroccan, and Turkish origin.
dUsing the Chi-squared test for categorical variables and the Kruskal-Wallis test for continuous variables.
eNugent scoring of Gram stains was performed during the all scheduled study visits in the VMB study, the first study visit in the HARP study, and not at all in the HELIUS study.
fBased on the rarefied sequencing data set of each of the studies.
gThe HARP and HELIUS studies also identified samples that had significant abundance of Bifidobacteria (n = 2 in HARP and n = 8 in HELIUS).
hThese pathobiont genera were uncommon (mean relative abundance lower than 1% for each of the genera).
iAlso includes reads assigned to the pathogens Chlamydia, Neisseria, and Treponema genus.
j Individual pathobionts in this rest group were detected at a mean estimated concentration of at most 0.02 log10 cells/µl in the Rwanda VMB study.
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van de Wijgert et al. Pathobionts in the Vaginal Microbiota
FIGURE 1 | Bar charts by study, intervention exposure (VMB Rwanda) and ethnic group (HELIUS). (A) Mean relative abundance of bacterial groups. (B) Cumulative
percentage of women with a specific VMB type. BV, bacterial vaginosis; BD, Bifidobacterium-dominated; BV_GV, polybacterial Gardnerella vaginalis-containing;
BV_noGV, polybacterial but low G. vaginalis; CI, confidence interval; GV, G. vaginalis-dominated; interv, (study product) interventions; LA, lactobacilli and anaerobes;
Lcr, L. crispatus-dominated; Li, L. iners-dominated; Lo, other lactobacilli-dominated; NA, not applicable; PB, pathobionts-containing; SA, South-Asian; SSA,
sub-Saharan African; VMB, vaginal microbiota; VMB-RW, Rwanda VMB study. Rwanda VMB study samples collected at the screening and Month 6 visits in all
randomization groups, and at the Month 1 and Month 2 visits in the no-intervention group, were considered not influenced by the interventions.
and BD 0.5%. The latter VMB type included only 10 samples
and was therefore not included in subsequent comparisons.
Consistent with the bacterial group findings, the VMB types
characterized by lactobacilli-domination (Li, Lcr, and Lo; 44.5%)
or by anaerobic dysbiosis (LA, BV_GV, BV_noGV, GV; 49.9%)
were much more common than the VMB type characterized
by ≥20% pathobionts (5.2%). VMB type distributions differed
significantly between the studies and strata, following the same
patterns as described above for the bacterial group findings
(Table 3, Figure 1B).
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Identification of Common Vaginal
Pathobionts
We identified 40 different pathobiont taxa in all 2,044
samples combined (Supplementary Material 1; reported at
species level if only one species was identified, genus level if
multiple species and/or the genus was identified, and family
or class level if only that level was identified). However,
20 of these were never a non-minority taxon (defined as
present at a relative abundance of at least 1% in at least
one sample) in any of the studies. Only six taxa were
a non-minority taxon in all three studies: Streptococcus,
Staphylococcus, Enterococcus, Escherichia/Shigella, Haemophilus,
and Campylobacter. Chlamydia was consistently detected in all
three studies but only as a non-minority taxon in HELIUS,
and Neisseria and Treponema were detected in the two
African studies only. The remaining 11 taxons varied in their
detection (yes vs. no) and relative abundance (minority vs.
non-minority) status between the three studies. More than
half (54%) of all pathobiont sequencing reads were assigned
to Streptococcus genus/species and 24% of the Streptococcus
reads were assigned to S. agalactiae or S. agalactiae/pyogenes.
Seventeen percent of all women (196/1,153) at baseline, and
19.5% (399/2,044) of all samples, had at least 1% pathobionts
in their VMB; these proportions were 12.7% (147/1,153), and
14.9% (304/2,044) for at least 1% Streptoccoccus. Among samples
with ≥20% pathobionts (N = 107; Supplementary Material 2,
Table S1), 33 contained Streptococcus genus/species as the only
pathobionts (relative abundances of 0.53–0.98) and an additional
52 contained multiple pathobionts including substantial relative
abundances of Streptococcus genus/species (0.13–0.73). The
other 22 samples contained other pathobionts (most commonly
staphylococci, Escherichia/Shigella species, Haemophilus species,
and/or enterococci), with <5% Streptococcus.
Of note, the total estimated bacterial concentration differed
significantly per VMB type (Table 4; data available for the
Rwanda VMB study only). The mean total bacterial estimated
concentration of women with the PB VMB type (5.85 log10
cells/µl) was comparable to those of women with Lactobacillus-
dominated VMB types (5.13–5.83 log10 cells/µl) but lower than
those of women with VMB types associated with anaerobic
dysbiosis (6.11–6.87 log10 cells/µl). When samples were stratified
by the proportion of pathobionts in the VMB (<1%, 1-
<10%, 10%-<20%, 20-<50%, and ≥50%), the mean estimated
concentration of pathobionts increased as expected, but reached
a plateau at proportions of 10% or more. The mean estimated
concentration of total bacteria remained stable but declined
somewhat when the pathobionts proportion reached above 20%.
Results were similar when only samples not influenced by
interventions were included in these analyses (Table 4).
Correlations Between Vaginal Pathobionts
and Other VMB Characteristics
We next investigated correlations between pathobionts levels
(relative abundances or estimated concentrations), lactobacilli
levels, and BV-anaerobes levels for samples not influenced by
interventions (Table 5). With increasing pathobionts proportion
(from <1% to 1-<10% to 10%-<20%, etc.), the mean relative
abundance of lactobacilli declined significantly (ρ = −0.1851;
95% confidence interval (CI) −0.2286 to −0.1416). The same
applied to estimated concentrations, but this trend was not
significant (ρ = −0.0132; 95% CI −0.1891 to 0.1627). We
could not detect a pathobionts proportion threshold: the weak
negative effect on lactobacilli was detectable even in the lowest
pathobionts proportion categories. By contrast, the mean relative
abundance of BV-anaerobes remained stable initially, and only
declined when pathobionts made up 30% or more of the VMB.
The mean BV-anaerobes estimated concentration significantly
increased with increasing estimated pathobionts concentration
and did not reach a plateau. In all pathobionts concentration
categories, BV-anaerobes outnumbered pathobionts.
Correlation matrixes for samples not influenced by
interventions confirmed that relative abundances of BV-
anaerobes and lactobacilli were strongly negatively correlated
(ρ = −0.9234; Figure 2A), but showed that their estimated
concentrations were not correlated (r = 0.0031; Figure 2B;
for correlation coefficients with 95% confidence intervals,
see Supplementary Material 2, Table S2). Pathobionts and
lactobacilli relative abundances were also negatively correlated,
albeit less strongly (ρ = −0.2076), and their estimated
concentrations were not (r = 0.0436). Pathobionts and BV-
anaerobes relative abundances were not correlated (ρ = 0.0160)
and their estimated concentrations were weakly positively
correlated (r = 0.1938). Pathobionts also correlated positively
with the “other bacteria” rest group (ρ = 0.3831 for relative
abundances and r = 0.3388 for estimated concentrations).
At individual genus level, the estimated concentrations of
the six pathobionts that were a non-minority genus in all
three studies correlated positively with one another except
for Campylobacter with the other five taxa, and Haemophilus
and Escherichia/Shigella.
Correlates of Vaginal Pathobionts
Detection
Finally, we investigated the correlates of pathobionts detection
(≥1% vs.<1%), relative abundance, and estimated concentration
for all studies combined (Table 6) and for each study separately
(Supplementary Material 2, Tables S3A–C). The mean relative
abundance and mean estimated concentration of pathobionts
decreased with increasing age (except in the HELIUS study),
and with ethnicities other than Dutch. The data consistently
showed strong associations with Nugent score categories in both
studies that assessed these (the Rwanda VMB andHARP studies):
the likelihood of detection (OR = 5.29; 95% CI 2.82–9.90),
mean relative abundance, and mean estimated concentration
of pathobionts were highest for Nugent score category 4–6
(intermediate), followed by 7–10 (BV-positive), and 0–3 (BV-
negative). Positive associations between pathobionts detection
or levels and hormonal contraceptive use, smoking, antibiotic
use in the 14 days prior to sampling, HIV status, and the
presence of STI pathogens were found in at least one but not
in all studies. Associations with sexual risk-taking and unusual
vaginal discharge reporting were inconsistent between studies,
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TABLE 4 | Estimated bacterial concentration per VMB type and by proportion of pathobionts (Rwanda VMB study only, multiple samples per woman).
VMB type Estimated total bacterial concentration in log10 cells/µl
N All samples
Mean (95% CI)b
N Not influenced by interventionsa
Mean (95% CI)c
Lactobacillus iners-dominated (Li) 144 5.81 (5.69–5.92) 34 5.99 (5.75–6.22)
L. crispatus-dominated (Lcr) 9 5.36 (4.99–5.72) 3 5.43 (4.51–6.35)
Other lactobacilli-dominated (Lo) 10 5.13 (4.63–5.64) 3 5.59 (4.13–7.05)
Lactobacilli and BV-anaerobes (LA) 57 6.31 (6.11–6.51) 21 6.34 (5.96–6.73)
Polybacterial Gardnerella vaginalis-containing (BV_GV) 90 6.87 (6.72–7.02) 57 6.91 (6.72–7.11)
Polybacterial but low G. vaginalis (BV_noGV) 16 6.29 (5.75–6.82) 14 6.15 (5.57–6.73)
G. vaginalis-dominated (GV) 27 6.11 (5.77–6.46) 16 6.14 (5.64–6.64)
Pathobionts-containing (PB) 26 5.85 (5.43–6.27) 10 5.76 (4.76–6.76)
Proportion pathobionts Estimated total bacterial concentration in log10 cells/µl
<1% 289 6.17 (6.07–6.27) 124 6.47 (6.31–6.62)
1%–<10% 50 6.14 (5.89–6.38) 19 6.05 (5.69–6.42)
10%–<20% 14 6.33 (5.89–6.78) 5 6.29 (5.02–7.56)
20%–<50% 15 6.04 (5.49–6.59) 8 6.18 (5.22–7.15)
≥50% 11 5.59 (4.84–6.34) 2 4.06 (−5.20–13.33)
Proportion pathobionts Estimated pathobionts concentration in log10 cells/µl
<1% 289 1.36 (1.16–11.56) 124 1.32 (0.99–1.65)
1%–<10% 50 4.38 (4.12–4.63) 19 4.21 (3.84–4.58)
10%–<20% 14 5.25 (4.80–5.69) 5 5.21 (4.00–6.41)
20%–<50% 15 5.40 (4.85–5.94) 8 5.51 (4.51–6.50)
≥50% 11 5.41 (4.71–6.12) 2 4.00 (−6.02–14.02)
BV, bacterial vaginosis; CI, confidence interval; VMB, vaginal microbiota.
aEstimated concentrations were only available for the Rwanda VMB study. Samples collected at the screening and Month 6 visits in all randomization groups, and at the Month 1 and
Month 2 visits in the no-intervention group, were considered not influenced by the interventions.
bThe Kruskall Wallis p-values comparing the relevant categories are <0.001 for VMB types and estimated total bacterial concentration, 0.606 for pathobionts proportion and estimated
total bacterial concentration, and <0.001 for pathobionts proportion and estimated pathobionts concentration.
The Kruskall Wallis p-value comparing the relevant categories are <0.001 for VMB types, 0.061 for pathobionts proportion and estimated total bacterial concentration, and <0.001 for
pathobionts proportion and estimated pathobionts concentration.
and we did not find associations with detection of vaginal yeasts
by microscopy.
DISCUSSION
Seventeen percent of this highly diverse group of women
from Africa and Europe had a VMB containing at least 1%
pathobionts, and 5.2% had a VMB containing at least 20%
pathobionts. Streptococcus was most common (54% of the
pathobionts sequencing reads), but Staphylococcus, Enterococcus,
Escherichia/Shigella, Haemophilus, and Campylobacter were also
detected as non-minority genera in all three studies. Mean
relative abundances and estimated concentrations of pathobionts
were much lower than those of lactobacilli and BV-anaerobes,
but the pathogenic potential may be higher, and these levels may
therefore be clinically relevant.
The meta-analysis confirmed that the VMB of many
women contains both lactobacilli and BV-anaerobes, but that
the BV-anaerobes concentration is low in “healthy” women
with lactobacilli-domination. Our relative abundance, estimated
concentration, and correlation data may be best explained by
the following hypothesis. BV-anaerobes are present or frequently
introduced into the vagina of most women, and may start to
expand in response to a trigger, such as recent sex or menses
(Jespers et al., 2017). When the BV-anaerobes concentration
increases, the lactobacilli concentration does not seem to decline
much initially, but instead, the total bacterial concentration
increases. The lactobacilli relative abundance therefore does
decline. We cannot test this hypothesis directly because our
analyses were cross-sectional, but the strong negative correlation
between lactobacilli and BV-anaerobes relative abundances (ρ
= −0.9234) but not estimated concentrations (r = 0.0031),
and the higher overall bacterial load of the anaerobic dysbiotic
VMB types (means 6.11–6.87 log10 cells/µl) compared to
the lactobacilli-dominated VMB types (means 5.13–5.83 log10
cells/µl) fit this hypothesis.
By contrast, a much smaller proportion of women in
our study carried pathobionts in their VMB (17% if a
1% relative abundance is used as a cut-off). Our relative
abundance, estimated concentration, and correlation data may
be best explained by the following hypothesis. Pathobionts are
occasionally introduced into the vagina from the gut, urinary
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TABLE 5 | VMB correlates by pathobionts relative abundance category, all samples from all studies not influenced by interventions (N = 1,781)a.
Cells: mean relative
abundance (95% CI)
Total pathobionts relative abundance category ρ (95% CI) r (95% CI)
<1% 1%–<10% 10%–<20% 20%–<30% 30%–<40% 40%–<50% ≥50% All b If ≥1%c
(n = 1,445) (n = 205) (n = 38) (n = 15) (n = 15) (n = 14) (n = 39) (N = 1,781) (n = 326)
Total pathobionts 0
(0–0)
0.03
(0.03–0.03)
0.15
(0.14–0.16)
0.25
(0.23–0.27)
0.35
(0.33–0.37)
0.46
(0.44–0.47)
0.81
(0.76–0.85)
NA NA
Total lactobacilli 0.55
(0.53–0.57)
0.45
(0.39–0.50)
0.25
(0.14–0.36)
0.21
(0.05–0.36)
0.24
(0.10–0.39)
0.15
(0.05–0.25)
0.07
(0.03–0.10)
−0.1851
(−0.2286, −0.1416)
−0.3756
(−0.4340,−0.3172)
Total BV-anaerobes 0.44
(0.42–0.46)
0.46
(0.41–0.51)
0.52
(0.41–0.64)
0.53
(0.38–0.68)
0.33
(0.20–0.46)
0.35
(0.24–0.46)
0.10
(0.06–0.13)
−0.0012
(−0.0453, 0.0429)
−0.3223
(-0.3946,−0.2501)
Total other bacteria 0.01
(0.00–0.01)
0.06
(0.04–0.09)
0.08
(0.01–0.15)
0.01
(0.00–0.02)
0.08
(0.00–0.15)
0.04
(0.00–0.07)
0.02
(0.01–0.04)
0.3894
(0.3464, 0.4323)
−0.0866
(−0.1356, −0.0376)
Lactobacillus iners 0.37
(0.35–0.39)
0.32
(0.27–0.36)
0.21
(0.11–0.32)
0.18
(0.04–0.32)
0.17
(0.04–0.31)
0.08
(-0.01–0.16)
0.04
(0.01–0.07)
−0.1564
(−0.2020, −0.1106)
−0.3069
(-0.3584,−0.2553)
L. crispatus 0.13
(0.12–0.15)
0.10
(0.07–0.13)
0.03
(−0.01–0.08)
0.01
(−0.01–0.03)
0.02
(0.00–0.04)
0.05
(−0.01–0.12)
0.02
(0.00–0.04)
0.0470
(0.0022, 0.0919)
−0.1484
(−0.1953, −0.1061)
Other lactobacilli 0.04
(0.04–0.05)
0.03
(0.02–0.04)
0.01
(0.00–0.01)
0.02
(0.00–0.03)
0.05
(−0.03–0.14)
0.02
(−0.01–0.06)
0.01
(−0.01–0.03)
0.0397
(−0.0272, 0.5989)
−0.0700
(−0.1290, −0.0010)
Gardnerella vaginalis 0.18
(0.17–0.19)
0.17
(0.14–0.20)
0.20
(0.12–0.28)
0.29
(0.12–0.45)
0.17
(0.05–0.29)
0.15
(0.06–0.25)
0.04
(0.01–0.07)
0.0038
(−0.0408, 0.0485)
−0.1759
(−0.2390, −0.1129)
Atopobium vaginae 0.04
(0.04–0.05)
0.02
(0.01–0.03)
0.02
(0.00–0.03)
0.04
(−0.02–0.11)
0.00
(0.00–0.01)
0.01
(0.00–0.02)
0
(0–0.01)
−0.1102
(−0.1560, −0.0643)
−0.1032
(−0.1567, −0.0496)
Prevotella species 0.05
(0.04–0.05)
0.07
(0.05–0.08)
0.09
(0.04–0.14)
0.03
(0.00–0.05)
0.05
(0.00–0.09)
0.04
(0.01–0.06)
0.01
(0.00–0.02)
0.0551
(0.0077, 0.1025)
−0.1961
(−0.2490, −0.1433)
Other BV-anaerobes 0.17
(0.16–0.19)
0.20
(0.17–0.24)
0.21
(0.15–0.28)
0.18
(0.06–0.30)
0.11
(0.04–0.19)
0.15
(0.05–0.25)
0.04
(0.02–0.06)
0.0504
(0.0040, 0.0968)
−0.2382
(−0.2994, −0.1771)
Cells: mean estimated
concentration in log10
cells/µL (95% CI)d
<103 103-<104 104-<105 105-<106 ≥106 ρ (95% CI)
Allb
r (95% CI)
If ≥1%c
(n = 89) (n = 33) (n = 21) (n = 10) (n = 5) (n = 158) (n = 34)
Total pathobionts 0.25
(0.09–0.40)
3.59
(3.48–3.70)
4.51
(4.37–4.65)
5.40
(5.23–5.56)
6.50
(5.92–7.09)
NA NA
Total bacteria 6.30
(6.10–6.49)
6.12
(5.83–6.42)
6.45
(6.00–6.91)
7.04
(6.43–7.65)
7.46
(7.18–7.74)
0.1219
(−0.0374, 0.2811)
0.8117
(0.7200, 0.9034)
Total lactobacilli 4.98
(4.70–5.26)
4.68
(4.12–5.24)
4.66
(3.71–5.62)
5.22
(3.68–6.76)
3.47
(−0.62–7.67)
−0.0132
(−0.1891, 0.1627)
0.0366
(−0.3937, 0.4669)
Total BV-anaerobes 5.60
(5.21–5.98)
5.55
(5.02–6.08)
5.88
(5.20–6.57)
6.68
(5.77–7.60)
7.22
(6.69–7.76)
0.1009
(−0.0596, 0.2615)
0.5778
(0.3391, 0.8166)
Total other bacteria 1.43
(1.05–1.81)
2.67
(2.05–3.28)
2.37
(1.41–3.33)
2.76
(0.99–4.52)
2.19
(−1.60–5.98)
0.2652
(0.1026, 0.4278)
0.0689
(−0.3669, 0.5048)
L. iners 4.65
(4.28–5.03)
4.31
(3.65–4.98)
4.54
(3.51–5.58)
5.22
(3.68–6.76)
3.29
(−0.60–7.19)
−0.0115
(−0.1817, 0.1588)
0.0891
(−0.3009, 0.4791)
L. crispatus 0.47
(0.19–0.74)
0.53
(0.02–1.05)
0.20
(−0.22–0.63)
0
(0–0)
1.28
(−2.28–4.85)
0.0325
(−0.1103, 0.1753)
0.2864
(−0.2120, 0.7849)
(Continued)
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.
tract, and perineum, or from the male partner external genitalia,
but are usually cleared or remain at low levels. If they do persist
and expand, lactobacilli decline somewhat, and BV-anaerobes
expand alongside the pathobionts. As before, we cannot test this
hypothesis directly, but the modest positive correlations between
estimated concentrations of pathobionts and BV-anaerobes,
the declines in estimated concentration/relative abundance of
lactobacilli with increasing pathobionts level, and an overall
bacterial load of the ≥20% pathobionts VMB type (5.85 log10
cells/µl) that is similar to that of the lactobacilli-dominated
VMB types (means 5.13–5.83 log10 cells/µl) fit this hypothesis.
Pathobionts also correlated positively with the “other bacteria”
group, which contains non-pathogenic skin bacteria such as
Corynebacterium. The pathobionts and non-pathogenic skin
bacteria may have been introduced into the vagina from the
woman’s perineum or the skin of the external genitalia of her
male partner, but specimen contamination via the hands of
specimen handlers cannot be ruled out.
Gram stain Nugent scoring is the current gold standard
for BV diagnosis (Nugent et al., 1991). In this method, Gram
stained slides are viewed under a microscopy, and three bacterial
morphotypes are scored: Gram-positive rods (presumed to
be lactobacilli), small Gram-variable rods (presumed to be
G. vaginalis), and curved Gram-variable rods (presumed to
be Mobiluncus). A Nugent score of 0–3 is considered BV-
negative, 4–6 intermediate microbiota, and 7–10 BV-positive.
In this meta-analysis, the likelihood of detection, mean relative
abundance, and mean estimated concentration of pathobionts
were consistently highest for Nugent score category 4–6, followed
by 7–10, and 0–3. These findings also fit the above-mentioned
hypotheses, and provide a partial explanation for what a Nugent
score of 4–6 signifies. A Nugent score of 4–6 should, however,
not be used to diagnose pathobionts presence because another
significant proportion of these samples likely contain lactobacilli
plus BV-anaerobes.
Positive associations between pathobionts detection and/or
levels and young age, non-Dutch origin, hormonal contraceptive
use, smoking, antibiotic use in the 14 days prior to sampling,
HIV status, and the presence of STI pathogens were found
in at least one study. All of these factors are also risk factors
for anaerobic dysbiosis, except for hormonal contraceptive use.
Hormonal contraception, and especially methods containing
estrogen, protects women from anaerobic dysbiosis (van de
Wijgert et al., 2013). Authors have hypothesized that estrogen
increases vaginal glycogen, which is converted into lactic acid
by lactobacilli. This keeps BV-anaerobes at bay but perhaps
not pathobionts. Streptococci, for example, can tolerate low
vaginal pH very well (Shabayek and Spellerberg, 2017). Sexual
risk-taking is an important proven risk factor for anaerobic
dysbiosis (van de Wijgert et al., 2014), but associations with
pathobionts detection and/or levels were inconsistent in this
meta-analysis. This could be due to the fact that women in
the two African cohorts were recruited based on sexual risk
or HIV-status, and women in the Dutch cohort were not,
thereby introducing collinearity between study/ethnic group and
sexual risk. Associations between pathobionts detection/levels
and unusual vaginal discharge reporting were also inconsistent
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FIGURE 2 | Correlation matrices. (A) Relative abundances, all three studies (N
= 1,781 samples)a. (B) Estimated concentrations, VMB study only (N = 158
samples)a. BV, bacterial vaginosis.aOnly includes VMB samples not influenced
by the interventions, collected at Screening, Month 6, and Month 1 and 2 in
the no-intervention group. Squares indicate the Spearman’s rank correlation
between −1 and +1. Positive correlations are shown in white and negative
correlations in black. The size of each square is loosely proportionate to the
magnitude of the correlation. For the actual correlation coefficients, (see
Supplementary Material, Tables S2C,D).
between studies. In our experience, vaginal symptom-reporting
rarely correlates well with the actual presence of a vaginal
infection or vaginal dysbiosis (Verwijs et al., 2019b). None of
the women in the three studies had severe symptoms, such as
those associated with desquamative inflammatory vaginitis, and
we could therefore not test the association between pathobionts
levels and such symptoms.
A limitation of our study is that each of the three studies
used slightly different sequencing-related laboratory and initial
data processing methods (Table 1). However, we took this into
account by stratifying most analyses by study. Another limitation
is that we did not detect and quantify individual pathobiont
species and genera by quantitative PCR. Past S. agalactiae
prevalence studies using selective culture have shown average
rectovaginal detection rates of 22% in sub-Saharan Africa and
19% in Europe (Kwatra et al., 2016), and a recent study using
quantitative PCR found a vaginal detection rate of 20% in Kenyan
women and 23% in South African women (Cools et al., 2016).
Detection of vaginal Streptococcuswas lower in our meta-analysis
when a relative abundance cut-off of 1% was used (12.7% of all
women at baseline; about a quarter of those were S. agalactiae).
It is currently not known how rectovaginal and vaginal selective
cultures, PCR, and sequencing results relate to one another, but
it is possible that pathobionts are not only under-detected in
sequencing studies due to the bioinformatics used, but also due
to DNA extraction, amplification, and other biases. For example,
the detection rate in the HARP study was especially low, which
may have been due to the fact that we did not use bead-beating
during DNA extraction in that study (Gill et al., 2016). Third,
some of the standard diagnostic tests that we used are known
to have lower sensitivity than NAAT-based tests (e.g., culture for
vulvovaginal candidiasis and T. vaginalis), and not all women in
all three studies were screened for all STI pathogens.
We also report some limitations related to our statistical
analyses. Correlating variables derived from relative abundance
data is problematic because they are not independent (Knight
et al., 2018); estimated concentrations of these same variables are
independent and did indeed provide new insights as described
above. However, we only had estimated concentration data for
the Rwanda VMB study. Furthermore, our analyses were cross-
sectional, and some of them had limited statistical power. Our
findings are therefore hypothesis-generating and the hypotheses
should be tested in well-powered longitudinal studies that assess
the VMB quantitatively. We did not exclude all women who had
recently used antibiotics, but reported antibiotic use in the last 2
weeks was rare. A strength of our study is the inclusion of women
and samples from three world regions and multiple ethnic
groups, and with different behaviors and STI pathogen exposures.
The variability in VMB compositions that we observed reflects
this wide variety of study participants.
CONCLUSION
While substantial presence of pathobionts in the VMB was
less common than anaerobic dysbiosis, the pathogenic potential
of pathobionts is higher than that of BV-anaerobes, and
modest levels could therefore be clinically relevant. The most
frequently used VMB types, and analyses limited to relative
abundance, are inadequate. We recommend that future etiologic
and intervention studies quantify the most common vaginal
pathobiont genera, as well as lactobacilli and BV-anaerobes.
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TABLE 6 | Correlates of pathobionts detection, relative abundance, and estimated concentration.
Rwanda VMB study screening, HARP baseline, and HELIUS samples All samples
Independent variablesa <1%
(% of N = 957)
≥1%
(% of N = 196)
OR (95% CI)b Pc Mean relative abundance
(95% CI); N = 2,044
Pc Mean estimated
concentration log10
cells/µl (95% CI); N = 379
Pc
Potentially influenced by interventions:d
- Yes
- No
NAd NAd NAd NAd 0.07 (0.04–0.09)
0.03 (0.03–0.04)
0.032 2.28 (1.99–2.57)
2.04 (1.69–2.38)
0.318
Age categories:
- 18–24
- 25–29
- 30–34
- 35–44
- 45–50
19.8
25.7
31.5
20.5
2.6
21.4
27.6
29.6
17.9
3.6
Reference
0.99 (0.63–1.54)
0.87 (0.56–1.34)
0.80 (0.49–1.31)
1.26 (0.51–3.11)
0.719 0.08 (0.06–0.11)
0.04 (0.03–0.05)
0.03 (0.02–0.03)
0.03 (0.02–0.04)
0.02 (0.01–0.04)
<0.001 3.09 (2.56–3.62)
2.29 (1.80–2.78)
2.01 (1.66–2.35)
1.63 (1.19–2.06)
NA
<0.001
Study or ethnicity:
- VMB Rwanda
- HARP South Africa
- HELIUS sub-Saharan African
- HELIUS Turkish, Moroccan, South-Asian
- HELIUS Dutch
14.2
38.6
16.9
21.2
9.1
13.3
38.8
10.7
31.1
6.1
1.39 (0.66–2.89)
1.49 (0.78–2.87)
0.94 (0.44–2.00)
2.18 (1.12–4.25)
Reference
0.013 0.06 (0.04–0.07)
0.03 (0.02–0.04)
0.03 (0.01–0.05)
0.04 (0.03–0.06)
0.01 (0.00–0.03)
<0.001 2.18 (1.96–2.40)
NA
NA
NA
NA
NA
Contraceptive use:
- None or condom use only
- Any oral contraception
- Progestin-only injectable
- Progestin-only implant
- Any IUD (copper or hormonal)
- Contraceptive ring
- NA (currently pregnant)
N = 954
58.0
20.7
11.9
3.1
5.7
0.6
0.6
61.2
19.4
8.2
5.6
4.6
1.0
0
Reference
0.89 (0.60–1.33)
0.65 (0.37–1.14)
1.74 (0.84–3.58)
0.76 (0.37–1.59)
1.53 (0.30–7.66)
ND
0.309
N = 1,768
0.03 (0.02–0.03)
0.03 (0.02–0.04)
0.05 (0.03–0.07)
0.04 (0.02–0.06)
0.01 (0.00–0.03)
0.02 (−0.02–0.05)
0 (0–0)
0.026
N = 252
1.53 (1.11–1.95)
2.89 (1.93–3.86)
2.37 (1.86–2.88)
2.58 (2.00–3.17)
1.55 (0.05–3.04)
NA
1.27 (−4.21–6.75)
0.014
Any hormonal contraception or pregnant:
- Yes
- No
N = 902
38.4
61.6
N = 188
35.6
64.4
0.87 (0.63–1.21)
Reference
0.415
N = 1,768
0.04 (0.03–0.05)
0.03 (0.02–0.03)
0.026
N = 252
2.50 (2.15–2.85)
1.53 (1.13–1.93)
<0.001
Current smoker:
- Yes
- No
N = 819
15.5
84.5
N = 170
13.5
86.5
0.85 (0.53–1.38)
Reference
0.508
N = 1,413
0.01 (0.00–0.03)
0.03 (0.02–0.04)
0.960 NA NA
Sample taken:e
- During or within 7 days after menses
- Not during or within 7 days after menses
NA NA NA NA
N = 462
0.05 (0.02–0.09)
0.08 (0.06–0.10)
0.236
N = 310
2.12 (1.63–2.62)
2.25 (1.97–2.53)
0.606
Any type of vaginal cleansing:
- Yes
- No
N = 871
30.7
69.4
N = 190
27.9
72.1
0.88 (0.62–1.24)
Reference
0.462
N = 1,320
0.03 (0.01–0.04)
0.04 (0.03–0.05)
0.805
N = 310
2.47 (1.82–3.11)
2.18 (1.92–2.44)
0.417
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TABLE 6 | Continued
Rwanda VMB study screening, HARP baseline, and HELIUS samples All samples
Independent variablesa <1%
(% of N = 957)
≥1%
(% of N = 196)
OR (95% CI)b Pc Mean relative abundance
(95% CI); N = 2,044
Pc Mean estimated
concentration log10
cells/µl (95% CI); N = 379
Pc
Number of sex partners prior to sampling:
- None
- One
- Two or more
21.4
57.1
21.4
25.6
52.3
22.1
Reference
0.77 (0.53–1.11)
0.86 (0.55–1.35)
0.379
N = 1,775
0.04 (0.02–0.06)
0.03 (0.01–0.03)
0.04 (0.02–0.05)
0.008
N=249
1.81 (−21.19–24.82)
1.82 (1.21–2.43)
2.17 (1.87–2.48)
0.571
Frequency of condom use:
- Never
- Inconsistent
- Consistent
- NA (no sexual partner)
20.5
30.8
26.8
21.9
18.4
28.6
27.6
25.5
Reference
1.04 (0.66–1.64)
1.15 (0.72–1.82)
1.30 (0.81–2.09)
0.659
N = 1,473
0.03 (0.01–0.04)
0.03 (0.02–0.04)
0.03 (0.02–0.05)
0.04 (0.02–0.06)
0.006
N=369
2.04 (1.19–2.89)
2.19 (1.90–2.47)
2.17 (1.76–2.58)
NA
0.955
Any antibiotic use in past 14 days:
- Yes
- No
N = 587
2.4
97.6
N = 119
4.2
95.8
1.80 (0.63–5.08)
Reference
0.293
N = 1,173
0.10 (0.06–0.14)
0.04 (0.03–0.05)
0.048 2.32 (1.94–2.69)
2.10 (1.83–2.38)
0.363
Current urogenital symptom:
- Yes
- No
N = 588
42.7
57.3
N = 120
42.5
57.5
0.99 (0.67–1.48)
Reference
0.970
N = 1,044
0.03 (0.02–0.05)
0.04 (0.03–0.05)
0.655 2.33 (1.71–2.95)
2.15 (1.91–2.39)
0.481
Current unusual vaginal discharge:
- Yes
- No
N = 588
17.7
82.3
N = 120
12.5
87.5
0.66 (0.37–1.19)
Reference
0.153
N = 1,044
0.02 (0.00–0.04)
0.04 (0.03–0.05)
0.371 2.65 (1.21–4.08)
2.16 (1.94–2.38)
0.386
Tested HIV-positive:f
- Yes
- No
40.0
60.0
39.8
60.2
0.99 (0.72–1.36)
Reference
0.953
N = 1,641
0.03 (0.02–0.03)
0.03 (0.02–0.04)
<0.001
N = 126
1.91 (−22.4–26.2)
1.84 (1.45–2.22)
0.983
Nugent score categories:f
- 0–3
- 4–6
- 7–10
N = 477
38.2
16.6
45.3
N = 96
17.7
40.6
41.7
Reference
5.29 (2.82–9.90)
1.98 (1.09–3.62)
<0.001
N = 893
0.01 (0.01–0.02)
0.06 (0.04–0.09)
0.02 (0.01–0.03)
<0.001
N = 364
1.61 (1.29–1.94)
2.78 (2.16–3.40)
2.25 (1.92–2.59)
0.001
Yeasts by microscopy:f
- Yes
- No
N = 477
8.0
92.0
N = 98
8.2
91.8
1.03 (0.46–2.27)
Reference
0.948
N = 905
0.02 (0.00–0.04)
0.03 (0.03–0.04)
0.846
N = 374
2.21 (1.33–3.08)
2.18 (1.94–2.41)
0.912
Trichomonas vaginalis by culture/NAAT:f
- Yes
- No
N = 935
7.7
92.3
N = 194
11.3
88.7
1.53 (0.93–2.54)
Reference
0.108
N = 1,462
0.02 (0.01–0.04)
0.03 (0.03–0.04)
0.806
N = 373
2.92 (1.89-3.95)
2.15 (1.92-2.37)
0.133
Chlamydia trachomatis by NAAT:f
- Yes
- No
N = 936
6.5
93.5
N = 194
4.6
94.4
0.70 (0.34–1.43)
Reference
0.307
N = 1,195
0.02 (0.00-0.05)
0.03 (0.02-0.03)
0.930
N = 126
2.74 (1.81-3.67)
1.60 (1.19-2.01)
0.019
Neisseria gonorrhoeae by NAAT:f
- Yes
- No
N = 936
2.2
97.8
N = 194
2.6
97.4
1.15 (0.43–3.10)
Reference
0.781
N = 1,195
0.01 (0–0.03)
0.03 (0.02–0.03)
0.650
N = 126
2.78 (1.67–3.89)
1.68 (1.28–2.08)
0.043
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TABLE 6 | Continued
Rwanda VMB study screening, HARP baseline, and HELIUS samples All samples
Independent variablesa <1%
(% of N = 957)
≥1%
(% of N = 196)
OR (95% CI)b Pc Mean relative abundance
(95% CI); N = 2,044
Pc Mean estimated
concentration log10
cells/µl (95% CI); N = 379
Pc
Mycoplasma genitalium by NAAT:f
- Yes
- No
N = 369
8.9
91.1
N = 76
6.6
93.4
0.72 (0.27–1.90)
Reference
0.489
N = 445
0.02 (0.00–0.03)
0.03 (0.02–0.04)
0.896 NA NA
Herpes simplex virus type 2 by serology:f
- Yes
- No
N = 503
87.1
12.9
N = 102
91.2
8.8
1.53 (0.74–3.19)
Reference
0.232
N = 627
0.02 (0.01–0.03)
0.02 (0.00–0.04)
0.054
N = 87
2.03 (1.33–2.74)
1.67 (1.02–2.33)
0.410
Active syphilis by serology:f
- Yes
- No
N = 502
2.8
97.2
N = 102
2.0
98.0
0.70 (0.16–3.12)
Reference
0.622
N = 668
0.01 (−0.01–0.03)
0.02 (0.02–0.03)
0.293
N = 126
1.87 (−1.33–5.07)
1.84 (1.45–2.22)
0.918
High-risk HPV by PCR:f
- Yes
- No
N = 821
52.5
47.5
N = 170
50.6
49.4
0.93 (0.67–1.29)
Reference
0.650
N = 1,415
0.03 (0.02–0.03)
0.03 (0.02–0.04)
0.107 NA NA
CI, confidence interval; HPV, human papilloma virus; IUD, intrauterine device; NA, not applicable; NAAT, nucleic acid amplification test; ND, not determinable; OR, odds ratio; PCR, polymerase chain reaction.
aRefer to the footnotes of Table 2 for other details regarding the independent variables tested in these logistic regression models.
bLogistic regression analysis with total pathobionts relative abundance (≥1 vs. <1%) as the outcome. All models contained the outcome and one independent variable.
cBy Kruskall–Wallis test, comparing mean pathobionts relative abundances or estimated concentrations between independent variable categories. For age, Spearman’s rank correlation was used, correlating age as a continuous variable
with pathobionts relative abundances or estimated concentrations as continuous variables.
dVMB study samples collected at the screening and Month 6 visits in all randomization groups, and at the Month 1 and Month 2 visits in the no-intervention group, and all HARP and HELIUS samples, were considered not influenced
by interventions.
eMenses data are only available for follow-up visits in the Rwanda VMB study.
f Includes samples from all study visits at which this outcome was tested (excluding invalid results, if applicable).
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Furthermore, the various detection and quantification methods
(culture, PCR, and sequencing) should be rigorously compared
to one another to facilitate interpretation of clinical study results.
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